单位：[1]Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA[2]Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA[3]Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, PR China[4]Wien Center, Mount Sinai Medical Center, Miami Beach, FL, USA[5]Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
Background African Americans (AA) remain underrepresented in Alzheimer's disease (AD) research, despite the prevalence of AD being double in AA compared to non-Hispanic whites. To address this disparity, our group has established the Florida Consortium for African American Alzheimer's Disease Studies (FCA3DS), focusing on the identification of genetic risk factors and novel plasma biomarkers. Method Utilizing FCA3DS whole exome sequence (WES) and plasma RNA samples from AD cases (n=151) and cognitively unimpaired (CU) elderly controls (n=269), we have performed differential gene expression (DGE) and expression quantitative trait locus (eQTL) analyses on 50 transcripts measured with a custom nanoString (R) panel. We designed this panel to measure, in plasma, cell-free mRNA (cf-mRNA) levels of AD-relevant genes. Findings Association with higher plasma CLU in CU vs. AD remained significant after Bonferroni correction. Study wide significant eQTL associations were observed with 105 WES variants in cis with 22 genes, including variants in genes previously associated with AD risk in AA such as ABCA7 and AKAP9. Results from this plasma eQTL analysis identified AD-risk variants in ABCA7 and AKAP9 that are significantly associated with lower and higher plasma mRNA levels of these genes, respectively. Receiver operating characteristic analysis of age, sex APOE-e4 dosage, CLU, APP, CD14, ABCA7, AKAP9 and APOE mRNA levels, and ABCA7 and AKAP9 eQTLs, achieved 77% area under the curve to discriminate AD vs. CU, an 8% improvement over a model that only included age, sex and APOE-e4 dosage. Interpretation Incorporating plasma mRNA levels could contribute to improved predictive value of AD biomarker panels. Copyright (C) 2022 The Author(s). Published by Elsevier B.V.
基金：
National Institute on Aging [RF AG051504, U01 AG046139, R01 AG061796, P30 AG062677]; Florida Health Ed and Ethel Moore Alzheimer's Disease [5AZ03, 7AZ17, 7AZ07, 8AZ08]
第一作者单位：[1]Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA
推荐引用方式(GB/T 7714)：
Reddy Joseph S.,Jin Jiangli,Lincoln Sarah J.,et al.Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans[J].EBIOMEDICINE.2022,78:doi:10.1016/j.ebiom.2022.103929.
APA：
Reddy, Joseph S.,Jin, Jiangli,Lincoln, Sarah J.,Ho, Charlotte C. G.,Crook, Julia E....&Carrasquillo, Minerva M..(2022).Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans.EBIOMEDICINE,78,
MLA：
Reddy, Joseph S.,et al."Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans".EBIOMEDICINE 78.(2022)
医学